Eddie Cliff
@eddiecliff.bsky.social
660 followers
190 following
15 posts
haematology registrar PMCC & RMH | research affiliate, PORTAL, BWH/HMS | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer
Posts
Media
Videos
Starter Packs
Reposted by Eddie Cliff
Reposted by Eddie Cliff
Reposted by Eddie Cliff
Reposted by Eddie Cliff
Reposted by Eddie Cliff
Eddie Cliff
@eddiecliff.bsky.social
· Apr 13
Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
This systematic review and meta-analysis examined non-relapse mortality, referring
to death unrelated to cancer relapse/progression, in patients with lymphoma and myeloma
treated with bispecific antib...
www.cell.com
Eddie Cliff
@eddiecliff.bsky.social
· Feb 16
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma
This narrative review explores how the identification of measurable residual disease through methods of detecting circulating tumor DNA contributes to outcomes for B-cell lymphomas.
jamanetwork.com
Eddie Cliff
@eddiecliff.bsky.social
· Feb 11
Eddie Cliff
@eddiecliff.bsky.social
· Feb 11
Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet
Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas.
Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains
an area of clinical and bi...
www.thelancet.com
Reposted by Eddie Cliff
Aaron Kesselheim
@akesselheim.bsky.social
· Jan 31
How to protect HHS, FDA, NIH, and other health agencies from political interference
When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts and inflict lasting damage on institutional credibility.
www.statnews.com
Reposted by Eddie Cliff
Joshua Sharfstein
@drjoshs.bsky.social
· Dec 17
Will The New Administration’s FDA Be A Threat Or An Opportunity For The Public's Health? | Health Affairs Forefront
As various reform ideas are proposed, the organized medical and scientific community will need to work with the new leadership at the FDA to promote positive change–and oppose initiatives that undermine the agency, its workforce, and its mission.
www.healthaffairs.org
Reposted by Eddie Cliff
Reposted by Eddie Cliff
Aaron Kesselheim
@akesselheim.bsky.social
· Nov 22
Reposted by Eddie Cliff
Aaron Kesselheim
@akesselheim.bsky.social
· Nov 23
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment
Many cancer drugs approved through the FDA's accelerated approval pathway do not offer
any survival benefit to patients. In this study, individuals expressed strong preferences
for certainty that a ca...
www.thelancet.com